Phase ii study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1055-1061

  Xue, C ^a   Huang, Y ^a   Huang, P Y ^a   Yu, Q T ^b   Pan, J J ^c   Liu, L Z ^a   Song, X Q ^b   Lin, S J ^c   Wu, J X ^a,d   Zhang, J W ^a   Zhao, H Y ^a   Xu, F ^a   Liu, J L ^a   Hu, Z H ^a   Zhao, L P ^a   Zhao, Y Y ^a   Wu, X ^a   Zhang, J ^a   Ma, Y X ^a   Zhang, L ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c Fujian Province Cancer Hospital   (China)

^d XIAMEN UNIVERSITY   (China)

Author keywords

Angiogenesis; Chemotherapy; Nasopharyngeal carcinoma; Sorafenib

Indexed keywords

CISPLATIN; FLUOROURACIL; SORAFENIB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONTINUOUS INFUSION; CONTRAST ENHANCED ULTRASONOGRAPHY; CONTRAST ENHANCEMENT; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOGRAPHY; EPISTAXIS; FATIGUE; FEMALE; GINGIVA BLEEDING; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEMATEMESIS; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PLEURA METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; THROMBOCYTOPENIA;

EID: 84875591271     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds581     Document Type: Article

References (44)

1. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal cancer. Cancer Treat Res 2003; 114: 275-293.
2. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 2011; 30: 114-119.
3. Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci 2008; 99: 1311-1318.
4. Xiao WW, Huang SM, Han F et al.. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: longterm results of a phase 2 study. Cancer 2011; 117: 1874-1883.
5. Wang TL, Tan YO. Cisplatin and 5-fluorouracil continuous infusion for metastatic nasopharyngeal carcinoma. Ann Acad Med Singapore 1991; 20: 601-603.
6. Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 1994; 5: 87-89.
7. Tan EH, Khoo KS, Wee J et al.. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 1999; 10: 235-237.
8. Yeo W, Leung TW, Chan AT et al.. A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer 1998; 34: 2027-2031.
9. Huang HQ, Cai QQ, Lin XB et al.. Preliminary result of multi-center clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi 2008; 30: 314-316.
10. Ma BB, Tannock IF, Pond GR et al.. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 2002; 95: 2516-2523.
11. Ngan RK, Yiu HH, Lau WH et al.. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol 2002; 13: 1252-1258.
12. Zhang L, Zhang Y, Huang PY et al.. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol 2008; 61: 33-38.
13. Zhang L, Zhao C, Peng PJ et al.. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 2005; 23: 8461-8468.
14. Ma BB, Hui EP, Wong SC et al.. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma - correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol 2009; 20: 1854-1859.
15. Wang CC, Chang JY, Liu TW et al.. Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma. Head Neck 2006; 28: 74-80.
16. Poon D, Chowbay B, Cheung YB et al.. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer 2005; 103: 576-581.
17. Chua DT, Sham JS, Au GK. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinumbased chemotherapy. Oral Oncol 2003; 39: 361-366.
18. Reck M, von Pawel J, Zatloukal P et al.. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
19. Tabernero J, Van Cutsem E, Diaz-Rubio E et al.. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25: 5225-5232.
20. Hui EP, Chan AT, Pezzella F et al.. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002; 8: 2595-2604.
21. Krishna SM, James S, Balaram P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 2006; 115: 85-90.
22. Wilhelm S, Carter C, Lynch M et al.. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5: 835-844.
23. Williamson SK, Moon J, Huang CH et al.. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010; 28: 3330-3335.
24. Elser C, Siu LL, Winquist E et al.. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-3773.
25. Flaherty KT, Schiller J, Schuchter LM et al.. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008; 14: 4836-4842.
26. Mross K, Steinbild S, Baas F et al.. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 2007; 43: 55-63.
27. Sun W, Powell M, O'Dwyer PJ et al.. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010; 28: 2947-2951.
28. Therasse P, Arbuck SG, Eisenhauer EA et al.. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
29. Capecitabine and cisplatin (XP)+sorafenib in advanced gastric cancer (AGC). http://clinicaltrials.gov/ct2/show/NCT00565370?term=sorafenib +cisplatin&rank=9 (29 May 2012 date last accessed).
30. Sorafenib, pemetrexed, and cisplatin in treating patients with advanced solid tumors. http://clinicaltrials.gov/ct2/show/NCT00703638?term=sorafenib +cisplatin&rank=5 (30 May 2012 date last accessed).
31. Lassau N, Lamuraglia M, Chami L et al.. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 2006; 187: 1267-1273.
32. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
33. Hui EP, Ma BB, King AD et al.. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol 2011; 22: 1280-1287.
34. Lee NY, Zhang Q, Pfister DG et al.. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 2012; 13: 172-180.
35. Lim WT, Ng QS, Ivy P et al.. A phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res 2011; 17: 5481-5489.
36. Nasopharyngeal carcinoma (NPC) axitinib. http://www.clinicaltrials.gov/ct2/show/NCT01249547?term=axitinib+NPC&rank=1. (29 May edition).
37. Zips D, Eicheler W, Geyer P et al.. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res 2005; 65: 5374-5379.
38. Hui EP, Leung SF, Au JS et al.. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 2004; 101: 300-306.
39. De Giorgi U, Aliberti C, Benea G et al.. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 2005; 11: 6171-6176.
40. Scagliotti G, Novello S, von Pawel J et al.. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1835-1842.
41. Gibson MK, Li Y, Murphy B et al.. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 3562-3567.
42. Shacham SE, Gava R, Figer A et al. Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors. J Clin Pharmacol 2012; 52 (5): 656-659.
43. Cohen EE, Davis DW, Karrison TG et al.. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10: 247-257.
44. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009; 10: 967-974.